Aardvark Therapeutics Inc

AARD remains in a Stage 2 advance with a clear HH/HL sequence and a supportive momentum breakout. After peaking on the July breakout, price formed an exhaustion candle and is now pulling back into the rising 9/21 EMAs above the 50 DMA. Options Score is overbought, so entries should be staged on pullbacks into the EMA zone or near the 50 DMA. A decisive break below these levels with sustained selling would negate the medium-term bullish thesis.

• ↑ARD-101 Phase II trial targets metabolic disorders with high market potential.
• ↑Dividend yield of 0.74% offers income amid uncertain capital gains.
• ↓Earnings yield of –3.41 indicates significant unprofitability versus price.